Skip to main content
padlock icon - secure page this page is secure

IL1β promotes osteogenic differentiation of mouse bone marrow mesenchymal stem cells via the BMP/Smad pathway within a certain concentration range

Buy Article:

$42.00 + tax (Refund Policy)

Inflammatory factors play an important role in the process of fracture healing. The influence of interleukin (IL)1β, a key inflammatory factory, on new bone formation has been controversial. The aim of the present study was to investigate whether IL1β affects the osteogenic differentiation of mouse bone marrow mesenchymal stem cells (MBMMSCs), and examined its effective concentration range and molecular mechanism of action. MBMMSC proliferation in the presence of IL1β was observed using a CellCounting Kit8 assay, and the effect of IL1β on MBMMSC apoptosis was examined via flow cytometry. Alkaline phosphatase assay, Alizarin Red staining and quantitative assays were performed to evaluate the osteogenic differentiation of MBMMSCs. The expression levels of osteogenic differentiation markers were detected using reverse transcriptionquantitative PCR (RTqPCR). It was demonstrated that within a concentration range of 0.011 ng/ml, IL1β promoted osteogenic differentiation of MBMMSCs and did not induce apoptosis. Furthermore, RTqPCR results indicated that IL1β increased osteogenic gene expression within this concentration range. Moreover, Western blotting results identified that the bone morphogenetic protein/Smad (BMP/Smad) signaling pathway was significantly activated by IL1β under osteogenic conditions. Therefore, the present results suggested that within a certain concentration range, IL1β promoted osteogenic differentiation and function of MBMMSCs via the BMP/Smad signaling pathway.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Document Type: Research Article

Affiliations: 1: Department of Orthopedics, Huainan First People's Hospital, Anhui University of Science and Technology, Huainan, Anhui 232000, P.R. China 2: Department of Orthopedics, Hefei First People's Hospital, Anhui Medical University, Hefei, Anhui 230000, P.R. China 3: Department of Orthopedics, Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui 230000, P.R. China

Publication date: October 1, 2020

More about this publication?
  • Experimental and Therapeutic Medicine aims to ensure the expedient publication, in both print and electronic format, of studies relating to biology, gene therapy, infectious disease, microbiology, molecular cardiology and molecular surgery. The journal welcomes studies pertaining to all aspects of molecular medicine, and studies relating to in vitro or in vivo experimental model systems relevant to the mechanisms of disease are also included.

    All materials submitted to this journal undergo the appropriate review via referees who are experts in this field. All materials submitted follow international guidelines with regard to approval of experiments on humans and animals.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Information for Advertisers
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more